• Home
  • NEW DAY MEDICINE
  • 1 (75) 2025
  • 35 -1 (75) 2025 - Agababyan I.R., Sadykova Sh.Sh. - ASSESSMENT OF THE EFFECTIVENESS OF GLP-1 AGONISTS IN NAFLD IN WOMEN OF DIFFERENT AGE GROUPS

35 -1 (75) 2025 - Agababyan I.R., Sadykova Sh.Sh. - ASSESSMENT OF THE EFFECTIVENESS OF GLP-1 AGONISTS IN NAFLD IN WOMEN OF DIFFERENT AGE GROUPS

ASSESSMENT OF THE EFFECTIVENESS OF GLP-1 AGONISTS IN NAFLD IN WOMEN OF DIFFERENT AGE GROUPS

Agababyan I.R. - Samarkand State Medical University Uzbekistan

Sadykova Sh.Sh. - Samarkand State Medical University Uzbekistan

Ismoilova Y.A. - Samarkand State Medical University Uzbekistan

Resume

To evaluate the effectiveness of GLP-1 agonists for non-alcoholic fatty liver disease in women of different age groups against the background of obesity and insulin resistance. 102 patients with non-alcoholic fatty liver disease at the steatosis stage were examined. The patients were divided into 2 groups: 1st group - main - 47 women of fertile age with non-alcoholic fatty liver disease, 2nd group - comparison - 55 women perimenopausal age with non-alcoholic fatty liver disease. 37 patients of them were practically healthy people and were selected as a control groupTo verify the diagnosis, in addition to general clinical data, we used the results of ultrasound examination of the liver, the determination of liver enzymes in blood serum and lipids. Bioimpedance measurements were performed on all patients to assess body fat (total and visceral fat) and muscle mass. The examined patients revealed significant changes in the blood lipid spectrum towards an increase in total cholesterol, low-density lipoproteins and triglycerides, and a decrease in the level of high-density lipoproteins. When analyzing bioimpedansometry data, a significant increase in the amount of total and visceral fat was noted, as well as a tendency towards a decrease in muscle mass. It has been established that the development of NAFLD is statistically significantly associated with an increase in the amount of adipose tissue (total and visceral fat) and a decrease in muscle mass associated with dyslipidemia. An increase in the amount of adipose tissue, including due to visceral fat, and a decrease in muscle mass are considered risk factors for the development of NAFLD.

Key words: total fat, visceral fat, pathogenesis of non-alcoholic fatty liver disease

First page

796

Last page

201

For citation:Agababyan I.R., Sadykova Sh.Sh., Ismoilova Y.A. - ASSESSMENT OF THE EFFECTIVENESS OF GLP-1 AGONISTS IN NAFLD IN WOMEN OF DIFFERENT AGE GROUPS//New Day in Medicine 1(75)2025 196-201 https://https://newdayworldmedicine.com/en/new_day_medicine/1-75-2025

List of References

  1. Mamasolievna J.N. Antidiabetic drugs in the treatment of non-alcoholic fatty liver disease: a literature review //Gospodarka i Innowacje. 2024;48:6-13.
  2. Mamasoliyevna D.N., Alisherovna K.M., Totlibayevich Y.S. Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: the Facets of Conjugacy //Miasto Przyszłości. 2023;35:166-173.
  3. Mayevskaya M.V. An effect of ursodeoxycholic acid on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with nonalcoholic fatty liver disease: Results of the USPEH Study / M.V.Mayevskaya, M.Yu.Nadinskaia, V.D.Lunkov et al. //Russian J. of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):22-29. (In Russ.) doi:10.22416/1382–4376–2019–29–6–22–29.
  4. Nonalcoholic fatty liver disease: a systematic review / M.E.Rinella //JAMA. 2015;313:2263-2273.
  5. Oliveros E., Somers V.K., Sochor O., Goel K., Lopez-Jimenez F. The concept of normal weight obesity //Progress in Cardiovascular Diseases. 2014;56(4):426-33. doi: 10.1016/j.pcad.2013.10.003.
  6. Rubenovna A. I., Mamasolievna J. N. (2024). Актуальные вопросы современного лечения неалкогольной жировой болезни печени. //Journal of biomediсine and praсtiсe 2024;9(2).
  7. Rubenovna A. I., Safronovna K. G., Sergeevna X. D., Alexandrovna K. N. (2024). Изучение компонентного состава организма на ранней стадии неалкогольной жировой болезни печени. //Journal of biomediсine and praсtiсe 2024;9(1).
  8. Rubеnоvnа А. I. еt аl. Изучение компонентного состава организма на ранней стадии неалкогольной жировой болезни печени //Jоurnаl оf biоmеdiсinе аnd prасtiсе. 2024;9(1).
  9. Агабабян И. Р., Джаббарова Н. М. (2023). Статины в лечении неалкогольной жировой болезни печени. //Zamonaviy fan va ta'lim yangiliklari xalqaro ilmiy jurnal 2023;1(4):104-116.
  10. Агабабян И. Р., Садыкова Ш. Ш. (2022). Выявление нарушений скорости клубочковой фильтрации в зависимости от степени ожирения (обзор литературы). //Журнал репродуктивного здоровья и уро-нефрологических исследований 2022;3(2).
  11. Агабабян И. Р., Садыкова Ш. Ш. (2022). Плейотропные эффекты статинов при неалкогольной болезни печени и неалкогольном стеатогепатите. //Рецепт 2022;(2):194-199.
  12. Агабабян И. Р. et al. "Оценка эффективности применение препарата Суфер у пациентов с нестабильной стенокардией и железодефицитной анемией." //Журнал “Узбекистон терапия ахборотномаси 2022;3.
  13. Белоусова Л. Н., Евдокимова Л. С., Евдокимов Д. С., Серкова М. Ю., Бакулин И. Г. Стеатоз печени: поиск новых факторов риска. Биоимпедансный анализ и эластометрия при проведении скрининга //Доктор.Ру. 2018;7(151):6-10.
  14. Kim D., Kim W.R. Nonobese Fatty Liver Disease //Clin. Gastroenterol. Hepatol. 2017;15:474-485.
  15. Ярашева З.Х. и др. Эффективности оральных антикоагулянтов при неклапанной форме фибрилляции предсердий у лиц пожилого возрста //Евразийский журнал медицинских и естественных наук. 2022;2(6):179-184.

    file

    download